A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Dietary triggers such as gluten and highly fermentable oligo-, di- and monosaccharides and polyols (FODMAP)-containing foods have been associated with worsening irritable bowel syndrome (IBS) symptoms. However, the true impact of dietary restriction on IBS symptoms has remained unclear. The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) examining the efficacy of exclusion diets (we focused on low FODMAP and gluten-free diets (GFD)) in IBS. METHODS: We conducted a search of the literature using the electronic databases MEDLINE (1946 to November 2017), EMBASE (1974 to November 2017), Cochrane Central Register of Controlled Trials (November 2017), and Cochrane Database of Systematic Reviews (2005 to November, 2017) for RCTs of exclusion diets in IBS. Two independent reviewers screened citations and a third reviewer resolved disagreement. Two independent reviewers performed eligibility assessment and data abstraction. For inclusion, RCTs that evaluated an exclusion diet versus an alternative or usual diet and assessed improvement in either global IBS symptoms or abdominal pain were required. Data were synthesized as relative risk of symptoms remaining using a random effects model. Quality of evidence was assessed using GRADE methodology. RESULTS: A total of 1726 citations were identified. After full-text screening a total of nine studies were eligible for the systematic review. There were two RCTs of a GFD, involving 111 participants. Both selected patients who responded to a GFD and then randomized them to continue the diet or have the diet “spiked” with gluten. A GFD was associated with reduced global symptoms compared with a control diet (RR = 0.42; 95% CI 0.11 to 1.55;I2 = 88%), although this was not statistically significant. There were seven RCTs comparing a low FODMAP diet with various control interventions in 397 participants. A low FODMAP diet was associated with reduced global symptoms compared with control interventions (RR = 0.69; 95% CI 0.54 to 0.88;I2 = 25%). The three RCTS that compared low FODMAP diet with rigorous control diets had the least heterogeneity between studies, but also the least magnitude of effect. The overall quality of the data was “very low” according to GRADE criteria. CONCLUSIONS: There is insufficient evidence to recommend a GFD to reduce IBS symptoms. There is very low quality evidence that a low FODMAP diet is effective in reducing symptoms in IBS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, as reported in the prior meta-analysis, 161 the quality of evidence from these trials was very low, due to small sample sizes, difficulties in blinding and heterogeneity between studies.”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A low FODMAP diet was associated with a reduction in the risk of remaining symptomatic, compared with all control interventions (RR 0.71; 95% CI 0.61 to 0.83) (online supplemental figure 2).”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [161]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The update to the prior systematic review and meta-analysis, 161 used to inform this guideline, identified 11 trials comparing a low FODMAP diet with various dietary control interventions, including habitual diet, a high FODMAP diet, traditional dietary advice as recommended by NICE and the BDA or a sham diet, in 658 participants.”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [161]
The cited source says what the claim attributes to it.
In the citing paper
“The prior systematic review and meta-analysis identified only 2RCTs, 161 comprising 111 participants and noted that although a gluten-free diet was associated with a reduction in global symptoms compared with a control diet, this was not statistically significant (RR 0.42; 95% CI 0. 11 to 1 55).”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [161]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationGRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Self-citationA Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249 · cited 1×
“…0.82) 0.46 (0.25, 0.84) 0.44 (0.11, 1.71) 0.44 (0.11, 1.71) 0.69 (0.54, 0.88) 0.87 (0.62, 1.24) 0.69 (0.47, 1.01) 0.82 (0.66, 1.02) 68 Mclntosh 2016 Halmos 2014 Staudacher 2012 Subtotal (95% CI) Subtotal (95% CI) Total events Subtotal (95% CI) Total (95% CI) Total events Total events Total…”
InfluentialBiesiekierski, J. R., Peters, S. L., Newnham, E. D., Rosella, O., Muir, J. G., & Gibson, P. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.04.051 · Cited by 798
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
Palsson, O. S., Whitehead, W. E., van Tilburg, M. A. L., Chang, L., Chey, W., Crowell, M. D., Keefer, L., Lembo, A. J., Parkman, H. P., Rao, S. S. C., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.014 · Cited by 719 · cited 1×
“A positive diagnosis of IBS can be made on symptom-based criteria [4] and there are a number of different therapies including manipulating the microbiome and pharmacological and psychological approaches [5].”
BackgroundSelf-citationBiesiekierski, J. R., Newnham, E. D., Irving, P. M., Barrett, J. S., Haines, M., Doecke, J. D., Shepherd, S. J., Muir, J. G., & Gibson, P. R. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.487 · Cited by 717
Böhn, L., Störsrud, S., Törnblom, H., Bengtsson, U., & Simrén, M. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.105 · Cited by 655
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645 · cited 1×
“A positive diagnosis of IBS can be made on symptom-based criteria [4] and there are a number of different therapies including manipulating the microbiome and pharmacological and psychological approaches [5].”
BackgroundSelf-citationBöhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., Törnblom, H., & Simrén, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.054 · Cited by 606 · cited 1×
“H, random, 95% CI 1.1.1 Low FODMAP versus alternative diet Bohn 2015 Eswaran 2016 Staudacher 2017 Subtotal (95% CI) Total events 19 7 7 3 6 9 2 2 86 27 22 38 50 20 16 20 20 176 17 23 4 4 122 22 39 7 7 198 16 20 13 19 32 8 8 199 51 139 20 26 33 79 37 42 53 132 20.4% 11.7% 11.7% 3.9% 10.0% 13.9% 3.0%…”
InfluentialStaudacher, H. M., Lomer, M. C. E., Anderson, J. L., Barrett, J. S., Muir, J. G., Irving, P. M., & Whelan, K. (2012) · The Journal of Nutrition · doi:10.3945/jn.112.159285 · Cited by 590 · cited 1×
“…0.84) 0.44 (0.11, 1.71) 0.44 (0.11, 1.71) 0.69 (0.54, 0.88) 0.87 (0.62, 1.24) 0.69 (0.47, 1.01) 0.82 (0.66, 1.02) 68 Mclntosh 2016 Halmos 2014 Staudacher 2012 Subtotal (95% CI) Subtotal (95% CI) Total events Subtotal (95% CI) Total (95% CI) Total events Total events Total events Hustoft…”
InfluentialFood elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial
Atkinson, W., Sheldon, T. A., Shaath, N., & Whorwell, P. J. (2004) · Gut · doi:10.1136/gut.2003.037697 · Cited by 534
Food-Related gastrointestinal symptoms in the irritable bowel syndrome
Simrén, M., Månsson, A., Langkilde, A. M., Svedlund, J., Abrahamsson, H., Bengtsson, U., & Björnsson, E. S. (2001) · Digestion · doi:10.1159/000051878 · Cited by 529
FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial
McIntosh, K., Reed, D. E., Schneider, T., Dang, F., Keshteli, A. H., De Palma, G., Madsen, K., Bercik, P., & Vanner, S. (2017) · Gut · doi:10.1136/gutjnl-2015-311339 · Cited by 478
Staudacher, H. M., Lomer, M. C. E., Farquharson, F. M., Louis, P., Fava, F., Franciosi, E., Scholz, M., Tuohy, K. M., Lindsay, J. O., Irving, P. M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.010 · Cited by 430 · cited 7×
“Three studies [14, 15, 19] examined a low FODMAP versus an alternative diet encompassing 271 patients.”
BackgroundInfluentialEswaran, S. L., Chey, W. D., Han-Markey, T., Ball, S., & Jackson, K. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.434 · Cited by 383 · cited 1×
“H, random, 95% CI 1.1.1 Low FODMAP versus alternative diet Bohn 2015 Eswaran 2016 Staudacher 2017 Subtotal (95% CI) Total events 19 7 7 3 6 9 2 2 86 27 22 38 50 20 16 20 20 176 17 23 4 4 122 22 39 7 7 198 16 20 13 19 32 8 8 199 51 139 20 26 33 79 37 42 53 132 20.4% 11.7% 11.7% 3.9% 10.0% 13.9% 3.0%…”
InfluentialSelf-citationRao, S. S. C., Yu, S., & Fedewa, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13167 · Cited by 343
Between Celiac Disease and Irritable Bowel Syndrome: The “No Man's Land” of Gluten Sensitivity
Verdu, E. F., Armstrong, D., & Murray, J. A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.188 · Cited by 283
Hustoft, T. N., Hausken, T., Ystad, S. O., Valeur, J., Brokstad, K., Hatlebakk, J. G., & Lied, G. A. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.12969 · Cited by 218 · cited 2×
“[23] implemented a low FODMAP diet and 15 patients who responded to the diet were subsequently randomized to receive a supplement, either a placebo or one containing a FODMAP.”
MethodShahbazkhani, B., Sadeghi, A., Malekzadeh, R., Khatavi, F., Etemadi, M., Kalantri, E., Rostami-Nejad, M., & Rostami, K. (2015) · Nutrients · doi:10.3390/nu7064542 · Cited by 144
Pinto-Sanchez, M. I., Ford, A. C., Avila, C. A., Verdu, E. F., Collins, S. M., Morgan, D., Moayyedi, P., & Bercik, P. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.128 · Cited by 140
Self-citationLahner, E., Bellentani, S., Bastiani, R. D., Tosetti, C., Cicala, M., Esposito, G., Arullani, P., Annibale, B., & Study Group Primary Care in Gastroenterology of the Italian Society of Gastroenterology (2013) · United European Gastroenterology Journal · doi:10.1177/2050640613499567 · Cited by 85
Krogsgaard, L. R., Lyngesen, M., & Bytzer, P. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14065 · Cited by 77
The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review
Moayyedi, P., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Ford, A. C. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.21 · Cited by 54
Self-citation
Research works printed but not linked: 1
- Ford, 2014, Am J Gastroenterol, 109, S1
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Self-citationFord, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31548-8 · Cited by 818
Self-citationGlobal burden of irritable bowel syndrome: trends, predictions and risk factors
Black, C. J., & Ford, A. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0286-8 · Cited by 610
Self-citationBritish Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
“However, as reported in the prior meta-analysis, 161 the quality of evidence from these trials was very low, due to small sample sizes, difficulties in blinding and heterogeneity between studies.”
InfluentialSelf-citationACG Clinical Guideline: Small Intestinal Bacterial Overgrowth
Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000501 · Cited by 502
Metadata
- Authors
- Dionne, J., Ford, A. C., Yuan, Y., Chey, W. D., Lacy, B. E., Saito, Y. A., Quigley, E. M. M., & Moayyedi, P.
- Affiliations
- University of Leeds (GB)
- Houston Methodist (US)
- ORCID
- Venue
- American Journal of Gastroenterology
- Published
- 2018-09
- Volume
- 113
- Issue
- 9
- Pages
- 1290-1300
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2883916703
- Cited by
- 379
- References
- 26
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 49 · 2023: 39 · 2022: 42 · 2021: 48 · 2020: 103 · 2019: 46 · 2018: 6
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Funders
- American College of Gastroenterology
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- irritable bowel syndrome, gluten-free diet, low FODMAP diet, elimination diet, dietary therapy, abdominal pain, IBS symptom severity, dietary triggers, treatment efficacy comparison, quality of evidence
- MeSH terms
- Clinical Trials as Topic, Disaccharides, Fermentation, Glutens, Humans, Monosaccharides, Severity of Illness Index, Treatment Outcome, Irritable Bowel Syndrome, Diet, Carbohydrate-Restricted, Diet, Gluten-Free
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.